Should vericiguat be initiated in geriatric inpatients with heart failure with reduced ejection fraction and a worsening heart failure event prior to discharge?
Julie HiasLaura HellemansKarolien WalgraeveJos TournoyChristophe VandenbrieleLucas Van AelstLorenz Roger Van der LindenPublished in: European journal of hospital pharmacy : science and practice (2022)
Heart failure (HF) occurs predominantly in older adults. HF patients have an increased risk for an acute exacerbation, which commonly requires hospitalisation. Such a worsening HF (WHF) event has an impact on prognosis. Vericiguat is a novel agent which has been shown to reduce the HF hospitalisation risk in patients with a recent WHF event. It is not fully clear how to position this novel agent in geriatric HF inpatients.
Keyphrases
- acute heart failure
- heart failure
- end stage renal disease
- left ventricular
- ejection fraction
- newly diagnosed
- chronic obstructive pulmonary disease
- atrial fibrillation
- cardiac resynchronization therapy
- physical activity
- prognostic factors
- liver failure
- patient reported outcomes
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- aortic dissection